Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (61-70 of 210) with videos related to

Pageof 21
Sort By:
Clinical Breast Cancer|October 4, 2016
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based RegimensJennifer J Gao, Ming Tan, Paula R Pohlmann, et al.
The Oncologist|May 29, 2012
A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trialsDeliya R Banda, Alexander V Libin, Hong Wang, et al.
Advances in Therapy|November 28, 2015
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by AgeSandra M Swain, Raquel Nunes, Carl Yoshizawa, et al.
Contemporary Clinical Trials Communications|August 4, 2017
Focus on You: Cancer clinical trials perspectivesBrandi N Robinson, Antoinette F Newman, Sherrie F Wallington, et al.
The Breast Journal|March 11, 2004
CA 125 elevation in breast cancer: a case report and review of the literatureGregory D Leonard, Jennifer A Low, Arlene W Berman, et al.
JACC. Cardiovascular Imaging|August 11, 2018
Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?Chau T Dang, Anne Blaes, Filipa Lynce, et al.
Texas Heart Institute Journal|July 2, 2011
Cardiac dysfunction after cancer treatmentMichael S Ewer, Sandra M Swain, Daniela Cardinale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancerSherry X Yang, Richard M Simon, Antoinette R Tan, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 14, 2003
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitorErin R Lepper, Sandra M Swain, Antoinette R Tan, et al.
Clinical Breast Cancer|April 6, 2006
A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancerJanice M Walshe, Neelima Denduluri, Arlene W Berman, et al.
Pageof 21

Showing results (61-70 of 210) with videos related to

Sort By:
Pageof 21
Clinical Breast Cancer|October 4, 2016
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based RegimensJennifer J Gao, Ming Tan, Paula R Pohlmann, et al.
The Oncologist|May 29, 2012
A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trialsDeliya R Banda, Alexander V Libin, Hong Wang, et al.
Advances in Therapy|November 28, 2015
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by AgeSandra M Swain, Raquel Nunes, Carl Yoshizawa, et al.
Contemporary Clinical Trials Communications|August 4, 2017
Focus on You: Cancer clinical trials perspectivesBrandi N Robinson, Antoinette F Newman, Sherrie F Wallington, et al.
The Breast Journal|March 11, 2004
CA 125 elevation in breast cancer: a case report and review of the literatureGregory D Leonard, Jennifer A Low, Arlene W Berman, et al.
JACC. Cardiovascular Imaging|August 11, 2018
Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?Chau T Dang, Anne Blaes, Filipa Lynce, et al.
Texas Heart Institute Journal|July 2, 2011
Cardiac dysfunction after cancer treatmentMichael S Ewer, Sandra M Swain, Daniela Cardinale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancerSherry X Yang, Richard M Simon, Antoinette R Tan, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 14, 2003
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitorErin R Lepper, Sandra M Swain, Antoinette R Tan, et al.
Clinical Breast Cancer|April 6, 2006
A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancerJanice M Walshe, Neelima Denduluri, Arlene W Berman, et al.
Pageof 21